Request for hard reprints

JAK2 V617F

Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet
J Clin Oncol. 2011
Authors: Barbui T. et al.

Is the JAK2(V617F) mutation detectable in healthy volunteers?
Am J Hematol. 2010
Authors: Martinaud C. et al.

Uses and abuses of JAK2 and MPL mutation tests in myeloproliferative neoplasms a paper from the 2010 William Beaumont hospital symposium on molecular pathology.
J Mol Diagn. 2011
Authors: Tefferi A. et al.

BCR-ABL Mbcr

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.
J Clin Oncol. 2009
Authors: Baccarani M et al.

Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA.
Blood. 2010
Authors:White HE et al.

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS).
Blood. 2010
Authors: Hughes TP et al.

Reference Materials and BCR-ABL Quantitation.
Advance Laboratory. April 2011
Author: Hélène Peyro-Saint-Paul.

NPM1

Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group.
J Clin Oncol. 2011
Authors: Krönke J et al.

WT1

Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by Standardized WT1 Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet Study.
J Clin Oncol. 2009 Sep 14
Authors: Cilloni et al.

AML (AML1-ETO, BAALC, CBFβ-MYH11, MLL translocations, MN1, NPM1, PML-RARa, WT1)

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.
Blood. 2010
Authors: Döhner H et al.